NCT04302324 · OUTCOME

Time to Progression

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab · Source last updated 2026-05-20

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Approximately 3 years

What was measured

Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for Progressive Disease

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for Progressive Disease
reporting Status: NOT_POSTED
time Frame: Approximately 3 years
title: Time to Progression
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice